Cytovance® Biologics Promotes Matt Hamilton to Vice President, Finance

23 April 2019

OKLAHOMA CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, has promoted Matt Hamilton to Vice President, Finance. Mr. Hamilton will be leading the Finance and Accounting function.

Matt has been acting Vice President of Finance for the past ten months and was Director of FP&A prior to being promoted.  “With over 18 years’ experience in Finance, Matt brings great depth of experience in Finance,” said Joyce Johnson, VP of Human Resources.  “We are very fortunate and excited to promote Matt into this role and have him on our experienced executive team.  Matt’s knowledge and leadership skills continue to be a tremendous asset.”

Prior to Cytovance, Matt served as Corporate Controller for Serva Group, where he oversaw the accounting and finance functions for multiple manufacturing plants.  Prior to joining Serva Group, Matt held the position of Plant Controller for Johnson Controls, for their Unitary Products Group.  Matt holds a bachelor’s degree in accounting from the University of Oklahoma and is a Certified Public Accountant.

About Cytovance Biologics

Cytovance Biologics is a biopharmaceutical contract development manufacturing organization (CDMO) specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, and microbial fermentation, transgenic processes, and small scale "flex suite" programs. In addition to its clinical and commercial cGMP manufacturing services, the company offers cell line development, purification development, process development and validation, stability, and regulatory support services from its Oklahoma City state-of-the-art facilities.

Media Contact: Sam Townsend,

Primary Logo